Epalrestat

Generic Name: Epalrestat

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₁₃NO_₃S_₂

CAS Number: 82159-09-9

Unique Ingredient Identifier: 424DV0807X

Background: Epalrestat is under investigation in clinical trial NCT03244358 (Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer).

Indication: 适用于糖尿病神经性病变。

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Research of SORD-CMT Natural History and Epalrestat Treatment

Phase 2

Not yet recruiting

Conditions: Charcot-Marie-Tooth Disease (CMT)

Interventions: Drug: Epalrestat

First Posted Date: 2023-03-21

Last Posted Date: 2023-04-18

Lead Sponsor: The Third Xiangya Hospital of Central South University

Target Recruit Count: 30

Registration Number: NCT05777226

Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

Phase 3

Active, not recruiting

Conditions: Phosphomannomutase 2 Deficiency
Phosphomannomutase 2 Congenital Disorder of Glycosylation
Phosphomannomutase II Congenital Disorder of Glycosylation
Phosphomannomutase II Deficiency
Pmm2-CDG

Interventions: Drug: Placebo
Drug: Epalrestat

First Posted Date: 2021-06-14

Last Posted Date: 2024-06-03

Lead Sponsor: Maggie's Pearl, LLC

Target Recruit Count: 40

Registration Number: NCT04925960

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer

Phase 2

Terminated

Conditions: Triple Negative Breast Cancer

Interventions: Drug: Epalrestat

First Posted Date: 2017-08-09

Last Posted Date: 2021-01-29

Lead Sponsor: Sun Yat-sen University

Target Recruit Count: 12

Registration Number: NCT03244358

Locations: 🇨🇳
Sun Yat-sen University, Cancer Center, Guangzhou, Guangdong, China

Prev
1
Next

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy